Follow

Submissions from 2015

PDF

Giant Cell Tumor of the Larynx Treated by Surgery and Adjuvant Denosumab: Case Report and Review of the Literature, A. E. Yancoskie, D. K. Frank, J. E. Fantasia, S. Savona, N. Eiseler, I. Reder, and L. B. Kahn

PDF

"The Great Mimicker": An Unusual Etiology of Cytopenia, Diffuse Lymphadenopathy, and Massive Splenomegaly, M. Zaarour, C. Weerasinghe, E. Moussaly, S. Hussein, and J. P. Atallah

Link

Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer, M. Zaarour, C. Weerasinghe, B. Nazha, S. Hassan, and J. P. Atallah

Submissions from 2014

Link

Prognostic significance of isolated t(8:14) in chronic lymphocytic leukemia, J. R. Asirvatham, J. Brody, R. Vora, J. E. Kolitz, S. Z. Fields, C. Sreekantaiah, and X. M. Zhang

PDF

More than 9 years of continuous trastuzumab treatment in metastatic breast cancer without cardiac toxicity: a case report and literature review, F. Badulescu, A. Badulescu, D. Paul, C. F. Popescu, and C. Florescu

PDF

Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8, H. Becker, K. Maharry, K. Mrozek, S. Volinia, A. K. Eisfeld, M. D. Radmacher, J. Kohlschmidt, K. H. Metzeler, J. E. Kolitz, C. D. Bloomfield, and +14 additional authors

PDF

Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103), J. H. Beumer, K. Owzar, L. D. Lewis, C. Jiang, J. L. Holleran, S. M. Christner, W. Blum, S. Devine, J. E. Kolitz, M. J. Egorin, and +5 additional authors

PDF

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia, J. C. Byrd, J. R. Brown, S. O'Brien, J. C. Barrientos, N. E. Kay, N. M. Reddy, S. Coutre, C. S. Tam, S. P. Mulligan, P. Hillmen, and +25 additional authors

PDF

Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia, R. Claus, D. M. Lucas, A. S. Ruppert, K. E. Williams, D. Weng, K. Patterson, M. Zucknick, J. C. Barrientos, K. R. Rai, J. C. Byrd, and +13 additional authors

Link

The successful treatment of a recurrent intracranial, dural-based plasmacytoma with lenalidomide, C. E. Devoe, J. Y. Li, and A. M. Demopoulos

PDF

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia, R. R. Furman, J. P. Sharman, S. E. Coutre, B. D. Cheson, J. M. Pagel, P. Hillmen, J. C. Barrientos, A. D. Zelenetz, T. J. Kipps, S. M. O'Brien, and +17 additional authors

PDF

Expression and prognostic impact of lncRNAs in acute myeloid leukemia, R. Garzon, S. Volinia, D. Papaioannou, D. Nicolet, J. Kohlschmidt, P. S. Yan, K. Mrozek, D. Bucci, J. E. Kolitz, C. D. Bloomfield, and +15 additional authors

Link

Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia, J. Houldsworth, A. Guttapalli, V. Thodima, X. J. Yan, G. Mendiratta, T. Zielonka, G. Nanjangud, K. Rai, N. Chiorazzi, R. S. K. Chaganti, and +4 additional authors

PDF

IGHV1-69 B Cell Chronic Lymphocytic Leukemia Antibodies Cross-React with HIV-1 and Hepatitis C Virus Antigens as Well as Intestinal Commensal Bacteria, K. K. Hwang, A. M. Trama, D. M. Kozink, S. L. Allen, K. R. Rai, R. Catera, X. J. Yan, C. C. Chu, N. Chiorazzi, B. F. Haynes, and +12 additional authors

PDF

Lenalidomide and Rituximab for the Initial Treatment of Patients With Chronic Lymphocytic Leukemia: A Multicenter Clinical-Translational Study From the Chronic Lymphocytic Leukemia Research Consortium, D. F. James, L. Werner, J. R. Brown, W. G. Wierda, J. C. Barrientos, J. E. Castro, A. Greaves, A. J. Johnson, K. R. Rai, T. J. Kipps, and +2 additional authors

PDF

Recombinant Interleukin-2 in Patients Aged Younger Than 60 Years With Acute Myeloid Leukemia in First Complete Remission, J. E. Kolitz, S. L. George, D. M. Benson, K. Maharry, G. Marcucci, R. Vij, B. L. Powell, S. L. Allen, D. J. DeAngelo, Oncology Alliance Clinical Trials, and +8 additional authors

PDF

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML, J. E. Lancet, J. E. Cortes, D. E. Hogge, M. S. Tallman, T. J. Kovacsovics, L. E. Damon, R. Komrokji, S. R. Solomon, J. E. Kolitz, E. J. Feldman, and +3 additional authors

PDF

Epigenetics Meets Genetics in Acute Myeloid Leukemia: Clinical Impact of a Novel Seven-Gene Score, G. Marcucci, P. Yan, K. Maharry, D. Frankhouser, D. Nicolet, K. H. Metzeler, J. Kohlschmidt, K. Mrozek, J. E. Kolitz, C. D. Bloomfield, and +21 additional authors

PDF

Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia, C. Niederwieser, J. Kohlschmidt, S. Volinia, S. P. Whitman, K. H. Metzeler, A. K. Eisfeld, K. Maharry, P. Yan, J. E. Kolitz, C. D. Bloomfield, and +17 additional authors

Link

Assessing outcomes of adult oncology patients treated with linezolid versus daptomycin for bacteremia due to vancomycin-resistant Enterococcus, K. Patel, R. Kabir, S. Ahmad, and S. L. Allen

PDF

Prolonged survival in metastatic colorectal cancer following chemotherapy, D. Paul, M. Gold, and N. Nouraddin

Link

Movement toward Optimization of CLL Therapy, K. R. Rai and J. C. Barrientos

Link

Carfilzomib-related acute kidney injury may be prevented by N-acetyl-L-cysteine, R. Wanchoo, S. Khan, J. E. Kolitz, and K. D. Jhaveri

PDF

GAS6 expression identifies high-risk adult AML patients: potential implications for therapy, S. P. Whitman, J. Kohlschmidt, K. Maharry, S. Volinia, K. Mrozek, D. Nicolet, S. Schwind, H. Becker, J. E. Kolitz, C. D. Bloomfield, and +11 additional authors

PDF

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, J. A. Woyach, R. R. Furman, T. M. Liu, H. G. Ozer, M. Zapatka, A. S. Ruppert, L. Xue, D. H. H. Li, J. C. Barrientos, J. C. Byrd, and +15 additional authors